CA-ZYNGA
5.8.2021 22:10:32 CEST | Business Wire | Press release
Rollic, a subsidiary of Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today a studio milestone of surpassing 1 billion downloads across its diverse portfolio of hyper-casual games. As one of the largest hyper-casual publishers in the world, Rollic has created a unique development process that leverages data insights and rigorous testing to repeatedly design and publish hit hyper-casual titles. Rollic’s process generates universally fun game concepts that resonate in pop culture and quickly spread on leading social media networks like TikTok.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005074/en/
Rollic’s fast-growing portfolio includes 15 titles that have reached the #1 or #2 top free downloaded games position in the U.S. App Store. Breakout hits Hair Challenge, High Heels! and Tangle Master 3D have each generated over 100 million downloads worldwide. Rollic’s recently released title Queen Bee reached the #1 top free downloaded game position in the U.S. App Store in June, and Arrow Fest has risen to the #2 top free downloaded game position in the U.S. App Store since launching in June. High Heels! integrated a first-of-its-kind partnership with Kenneth Cole in June, debuting the iconic designer’s PRIDE 2021 collection in-game to celebrate diversity and raise awareness for the Mental Health Coalition.
“We are blown away by Rollic’s performance so far this year,” said Bernard Kim, Zynga’s President of Publishing. “Rollic is a unique publisher that is able to repeatedly publish games that surprise and delight players. They have invented a fresh approach to development that results in simple yet deeply engaging games with universal appeal.”
“I am immensely proud of the Rollic team for this momentous achievement. This milestone highlights Rollic’s ability to merge the art and science of game creation to develop titles that resonate with players from all walks of life,” said Burak Vardal, Co-Founder of Rollic. “By constantly improving our understanding of what today’s players seek, and creating hundreds of new game concepts each quarter, we are able to deliver fun and authentic titles that succeed in entertaining millions worldwide.”
Zynga acquired Rollic in October 2020, marking Zynga’s entry into hyper-casual. Founded in 2018 by Burak Vardal, Deniz Basaran and Mehmet Can Yavuz, Rollic has quickly established itself as a leader in the category with its innovative development process and exciting portfolio of hyper-casual games. Rollic’s games are available for iOS and Android devices in over 175 countries around the world.
To view supporting assets for Rollic and its games, please click here:
https://www.dropbox.com/sh/97plhmo4vnycx2c/AACrCuPm0jpAs8YDrynzz2sta?dl=0
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. With massive global reach in more than 175 countries and regions, Zynga has a diverse portfolio of popular game franchises that have been downloaded more than four billion times on mobile, including CSR Racing ™, Empires & Puzzles ™, Hair Challenge ™, Harry Potter: Puzzles & Spells ™, High Heels! ™, Merge Dragons! ™, Merge Magic! ™, Queen Bee ™, Toon Blast ™, Toy Blast ™, Words With Friends ™ and Zynga Poker ™. With Chartboost, a leading mobile advertising and monetization platform, Zynga is an industry-leading next-generation platform with the ability to optimize programmatic advertising and yields at scale. Founded in 2007, Zynga is headquartered in California with locations in North America, Europe and Asia. For more information, visit www.zynga.com or follow Zynga on Twitter , Instagram , Facebook or the Zynga blog .
About Rollic
Founded in December 2018, Rollic is an Istanbul-based game developer and publisher, focused on free-to-play hyper-casual games for iOS and Android. Games released by Rollic include Arrow Fest, Blob Runner 3D, Block Breaker Miner, Go Knots 3D, Hair Challenge, High Heels!, Onnect – Pair Matching Puzzle, Queen Bee, Ragdoll Fighter and Tangle Master 3D. Rollic is committed to producing massively appealing global titles while building a thriving developer ecosystem in the gaming industry. Rollic was acquired by Zynga, a global leader in interactive entertainment, in October 2020. For more information, visit www.rollicgames.com or follow Rollic on Facebook , LinkedIn , Instagram , Twitter or the Rollic blog .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom